ranibizumab
Cold Chain RequiredFDA Approved, EMA Approved
Description
Ranibizumab is a recombinant humanized monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). It is used to treat neovascular (wet) age-related macular degeneration and other retinal conditions. The drug works by preventing abnormal blood vessel growth and leakage in the retina.
Indications & Therapeutic Use
neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion
Linked Diseases:
macular degeneration
D008268
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
ranibizumab
| Generic Name | ranibizumab |
| Brands | 1 brand available |
| Active Ingredient | ranibizumab |
| Drug Class | neovascular age-related macular degeneration |
| Manufacturer | Genentech/Novartis |
| Dosage Forms | intravitreal injection, 10 mg/mL solution |
| Medical Code | S01LA04 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00056836 |
| Countries | 9 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations10 Validated Nodes